{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T18:33:27Z","timestamp":1765737207119,"version":"3.48.0"},"reference-count":26,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,5,24]]},"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Left ventricular assist devices (LVADs) have emerged as a successful treatment option for patients with end-stage heart failure. Compared with the best medical therapy, LVADs improve survival and enhance functional capacity and quality of life. However, two major complications compromise this patient population\u2019s outcomes: thrombosis and bleeding. Despite technological innovations and better hemocompatibility, these devices alter the rheology, triggering the coagulation cascade and, therefore, require antithrombotic therapy. Anticoagulation and antiplatelet therapies represent the current standard of care. Still, inconsistency in the literature exists, especially whether antiplatelet therapy is required, whether direct oral anticoagulants can replace vitamin K antagonists and even whether phosphodiesterase type 5 inhibitors with their antithrombotic effects could be added to the regimen of anticoagulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We will perform a living systematic review with network meta-analysis and indirect comparison between current antithrombotic therapies, which have and have not been directly compared within clinical trials and observational studies. We will systematically search the following electronic sources: Cochrane Central Register of Controlled Trials (CENTRAL), Medical Literature Analysis and Retrieval System Online (MEDLINE) and Excerpta Medica Database (EMBASE). We will exclusively examine studies published in English from 2016 to the present. Studies conducted before 2016 will be omitted since our primary focus is evaluating continuous flow devices. Two independent reviewers will assess the articles by title, abstract and full text; any disagreement will be resolved through discussion, and a third reviewer will be involved if necessary. The Cochrane Risk of Bias tool will be used to assess the risk of bias. We will then conduct a pairwise meta-analysis; if the assumption of transitivity is satisfied, we will proceed with network meta-analysis using Bayesian methodology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Formal ethical approval is not required as no primary data are collected. This systematic review and network meta-analysis will delineate the risks of stroke, thromboembolic events, pump thrombosis, gastrointestinal bleeding and mortality in patients equipped with LVADs who are subjected to various antithrombotic regimens. The findings will be disseminated via a peer-reviewed publication and presented at conference meetings. This will enhance clinical practice and guide future research on anticoagulation strategies within this distinct patient cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42023465288.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-080110","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T02:46:51Z","timestamp":1719370011000},"page":"e080110","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Antithrombotic therapy for durable left ventricular assist devices: protocol for a living systematic review with indirect comparison\/network meta-analysis"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3967-3574","authenticated-orcid":false,"given":"Simone Helena","family":"Derzi","sequence":"first","affiliation":[{"name":"Anesthesiology, University of Alberta, Edmonton, Alberta, Canada"},{"name":"University of Ottawa School of Epidemiology and Public Health, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6420-887X","authenticated-orcid":false,"given":"Omar","family":"Dewidar","sequence":"additional","affiliation":[{"name":"Center for Global Health, Bruyere Research Institute, Ottawa, Ontario, Canada"},{"name":"University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hind","family":"Sabri","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diem","family":"Tran","sequence":"additional","affiliation":[{"name":"University of Ottawa School of Epidemiology and Public Health, Ottawa, Ontario, Canada"},{"name":"University of Ottawa Heart Institute, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A","family":"Wells","sequence":"additional","affiliation":[{"name":"University of Ottawa School of Epidemiology and Public Health, Ottawa, Ontario, Canada"},{"name":"Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"2025121410322027000_14.6.e080110.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000757"},{"key":"2025121410322027000_14.6.e080110.2","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2016:25:2"},{"key":"2025121410322027000_14.6.e080110.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012175"},{"key":"2025121410322027000_14.6.e080110.4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.acvd.2020.03.017","article-title":"Pulsatility in ventricular assistance devices: a translational review focused on applied haemodynamics","volume":"113","author":"Lescroart","year":"2020","journal-title":"Arch Cardiovasc Dis"},{"key":"2025121410322027000_14.6.e080110.5","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11030757","article-title":"Vascular function in continuous flow lvads: implications for clinical practice","volume":"11","author":"Khalil","year":"2023","journal-title":"Biomedicines"},{"key":"2025121410322027000_14.6.e080110.6","unstructured":"Urgent Medical Device Communication Notification Letter Medtronic HVADTM System, Available: https:\/\/www.medtronic.com\/content\/dam\/medtronic-com\/global\/HCP\/Documents\/hvad-urgent-medical-device-notice-june-2021.pdf"},{"key":"2025121410322027000_14.6.e080110.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2012.09.013"},{"key":"2025121410322027000_14.6.e080110.8","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/ejcts\/ezz098","article-title":"EACTS expert consensus on long-term mechanical circulatory support","volume":"56","author":"Potapov","year":"2019","journal-title":"Eur J Cardiothorac Surg"},{"key":"2025121410322027000_14.6.e080110.9","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1001\/jama.2023.23204","article-title":"Aspirin and hemocompatibility events with a left ventricular assist device in advanced heart failure: the ARIES-Hm3 randomized clinical trial","volume":"330","author":"Mehra","year":"2023","journal-title":"JAMA"},{"key":"2025121410322027000_14.6.e080110.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2015.06.018"},{"key":"2025121410322027000_14.6.e080110.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2016.07.072"},{"key":"2025121410322027000_14.6.e080110.12","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/ejhf.1468","article-title":"Do we need aspirin in heartmate 3 patients?","volume":"21","author":"Consolo","year":"2019","journal-title":"European J of Heart Fail"},{"key":"2025121410322027000_14.6.e080110.13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MAT.0000000000000859","article-title":"Discontinuation of aspirin in heartmate 3 left ventricular assist device","volume":"65","author":"Lim","year":"2019","journal-title":"ASAIO J"},{"key":"2025121410322027000_14.6.e080110.14","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.healun.2019.02.013","article-title":"Low-intensity anti-coagulation using vitamin K antagonists and factor X activity: a validation analysis of the MAGENTUM-1 study","volume":"38","author":"Connors","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"2025121410322027000_14.6.e080110.15","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003709","article-title":"Increased thromboembolic events with dabigatran compared with vitamin K antagonism in left ventricular assist device patients: a randomized controlled pilot trial","volume":"10","author":"Andreas","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2025121410322027000_14.6.e080110.16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/MAT.0000000000001650","article-title":"Apixaban: alternative anticoagulation for heartmate 3 ventricular assist device","volume":"68","author":"Whitehouse","year":"2022","journal-title":"ASAIO J"},{"key":"2025121410322027000_14.6.e080110.17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.healun.2020.03.001","article-title":"Effect of aspirin dose on hemocompatibility-related outcomes with a magnetically levitated left ventricular assist device: an analysis from the MOMENTUM 3 study","volume":"39","author":"Saeed","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"2025121410322027000_14.6.e080110.18","doi-asserted-by":"crossref","first-page":"101506","DOI":"10.1016\/j.cpcardiol.2022.101506","article-title":"Anticoagulation alone as an effective and safe antithrombotic therapy in LVAD: when less is more","volume":"48","author":"Tarzia","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"2025121410322027000_14.6.e080110.19","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1097\/MAT.0000000000001421","article-title":"Impact of aspirin dosing on thrombotic outcomes in patients with the HVAD","volume":"67","author":"Simone","year":"2021","journal-title":"ASAIO J"},{"key":"2025121410322027000_14.6.e080110.20","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015897","article-title":"Postimplant phosphodiesterase type 5 inhibitors use is associated with lower rates of thrombotic events after left ventricular assist device implantation","volume":"9","author":"Xanthopoulos","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025121410322027000_14.6.e080110.21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jchf.2021.09.008","article-title":"Postimplant phosphodiesterase-5 inhibitor use in centrifugal flow left ventricular assist devices","volume":"10","author":"Xanthopoulos","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2025121410322027000_14.6.e080110.22","doi-asserted-by":"crossref","first-page":"100940","DOI":"10.1016\/j.cpcardiol.2021.100940","article-title":"Triple antithrombotic therapy in patients with left ventricular assist devices","volume":"47","author":"Krim","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"2025121410322027000_14.6.e080110.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2016.02.025"},{"key":"2025121410322027000_14.6.e080110.24","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2025121410322027000_14.6.e080110.25","unstructured":"INTERMACS User\u2019s guide, Available: https:\/\/intermacs.kirso.net\/intermacs-documents\/"},{"key":"2025121410322027000_14.6.e080110.26","unstructured":"Covidence systematic review software, veritas health innovation. 2023. Melbourne, Australia; 2023. Available: at www.covidence.org"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-080110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T18:32:28Z","timestamp":1765737148000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-080110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,25]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/bmjopen-2023-080110"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-080110","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}